尼达尼布在非小细胞肺癌患者中的疗效与安全性以及放射性肺损伤的新见解
Efficacy and safety of nintedanib in patients with non-small cell lung cancer, and novel insights in radiation-induced lung toxicity.
作者信息
Yan Shu, Xue Shuyu, Wang Tiantian, Gao Ruihang, Zeng Hanqiao, Wang Qianmeng, Jia Xiaojing
机构信息
Department of Tumor Radiotherapy, The Second Hospital of Jilin University, Changchun, China.
出版信息
Front Oncol. 2023 Aug 10;13:1086214. doi: 10.3389/fonc.2023.1086214. eCollection 2023.
Abstract
Nintedanib is a tyrosine kinase inhibitor of fibroblast growth factor-, vascular endothelial growth factor-, and platelet-derived growth factor receptors. These three receptors promote new blood vessel formation and maintenance, which is essential for tumor growth and spread. Several trials have shown that nintedanib plays a substantial role in treating patients with non-small cell lung cancer (NSCLC) and idiopathic pulmonary fibrosis. Recently, several clinical trials of nintedanib to treat NSCLC have been reported. In this review, we focus on our current understanding of nintedanib treatment for advanced NSCLC patients and summarize the literature on using nintedanib in radiation-induced lung toxicity and the efficacy and tolerability of nintedanib.
摘要
尼达尼布是一种成纤维细胞生长因子受体、血管内皮生长因子受体和血小板衍生生长因子受体的酪氨酸激酶抑制剂。这三种受体促进新血管的形成和维持，而这对于肿瘤的生长和扩散至关重要。多项试验表明，尼达尼布在治疗非小细胞肺癌（NSCLC）和特发性肺纤维化患者方面发挥着重要作用。最近，已有多项关于尼达尼布治疗NSCLC的临床试验报道。在本综述中，我们重点阐述了目前对尼达尼布治疗晚期NSCLC患者的认识，并总结了有关尼达尼布在放射性肺损伤中的应用以及尼达尼布的疗效和耐受性的文献。
相似文献
1
Efficacy and safety of nintedanib in patients with non-small cell lung cancer, and novel insights in radiation-induced lung toxicity.尼达尼布在非小细胞肺癌患者中的疗效与安全性以及放射性肺损伤的新见解
Front Oncol. 2023 Aug 10;13:1086214. doi: 10.3389/fonc.2023.1086214. eCollection 2023.
2
Nintedanib-A case of treating concurrent idiopathic pulmonary fibrosis and non-small cell lung cancer.尼达尼布——治疗特发性肺纤维化合并非小细胞肺癌1例
Respirol Case Rep. 2022 Jan 12;10(2):e0902. doi: 10.1002/rcr2.902. eCollection 2022 Feb.
3
Clinical development of nintedanib for advanced non-small-cell lung cancer.尼达尼布用于晚期非小细胞肺癌的临床开发。
Ther Clin Risk Manag. 2015 Nov 16;11:1701-6. doi: 10.2147/TCRM.S76646. eCollection 2015.
4
miR-200/ZEB axis regulates sensitivity to nintedanib in non-small cell lung cancer cells.微小RNA-200/锌指E盒结合蛋白轴调控非小细胞肺癌细胞对尼达尼布的敏感性。
Int J Oncol. 2016 Mar;48(3):937-44. doi: 10.3892/ijo.2016.3331. Epub 2016 Jan 11.
5
Nintedanib (OFEV) in the treatment of idiopathic pulmonary fibrosis.尼达尼布（维加特）用于治疗特发性肺纤维化。
Expert Rev Respir Med. 2016 Dec;10(12):1247-1254. doi: 10.1080/17476348.2016.1249854. Epub 2016 Oct 31.
6
Nintedanib (BIBF 1120) blocks the tumor promoting signals of lung fibroblast soluble microenvironment.尼达尼布（BIBF 1120）可阻断肺成纤维细胞可溶性微环境的促肿瘤信号。
Lung Cancer. 2016 Jun;96:7-14. doi: 10.1016/j.lungcan.2016.03.013. Epub 2016 Mar 26.
7
Advanced Delivery Strategies of Nintedanib for Lung Disorders and Beyond: A Comprehensive Review.尼达尼布在肺部疾病及其他领域的先进给药策略：全面综述。
AAPS PharmSciTech. 2024 Jul 1;25(6):150. doi: 10.1208/s12249-024-02869-9.
8
Second-Line Treatment of Non-Small Cell Lung Cancer: Clinical, Pathological, and Molecular Aspects of Nintedanib.非小细胞肺癌的二线治疗：尼达尼布的临床、病理及分子学方面
Front Med (Lausanne). 2017 Feb 28;4:13. doi: 10.3389/fmed.2017.00013. eCollection 2017.
9
Nintedanib-induced glomerular microangiopathy: a case report.尼达尼布致肾小球微血管病：病例报告。
CEN Case Rep. 2020 Nov;9(4):295-300. doi: 10.1007/s13730-020-00474-w. Epub 2020 Apr 11.
10
Triple Angiokinase Inhibitor Nintedanib Directly Inhibits Tumor Cell Growth and Induces Tumor Shrinkage via Blocking Oncogenic Receptor Tyrosine Kinases.三激酶抑制剂尼达尼布通过阻断致癌受体酪氨酸激酶直接抑制肿瘤细胞生长并诱导肿瘤缩小。
J Pharmacol Exp Ther. 2018 Mar;364(3):494-503. doi: 10.1124/jpet.117.244129. Epub 2017 Dec 20.
引用本文的文献
1
Targeting the Tumor Microenvironment in EGFR-Mutant Lung Cancer: Opportunities and Challenges.靶向表皮生长因子受体（EGFR）突变型肺癌的肿瘤微环境：机遇与挑战
Biomedicines. 2025 Feb 14;13(2):470. doi: 10.3390/biomedicines13020470.
2
KRAS -inhibitor-based combination therapies for pancreatic cancer: insights from drug screening.基于KRAS抑制剂的胰腺癌联合疗法：药物筛选的见解
Mol Oncol. 2025 Feb;19(2):295-310. doi: 10.1002/1878-0261.13725. Epub 2024 Sep 10.
3
Nintedanib in Combination With Chemotherapy in the Treatment of Non-small Cell Lung Cancer: A Systematic Review and Meta-Analysis.尼达尼布联合化疗治疗非小细胞肺癌：一项系统评价和荟萃分析。
Cureus. 2024 Feb 7;16(2):e53812. doi: 10.7759/cureus.53812. eCollection 2024 Feb.
4
Critical review of the current and future prospects of VEGF-TKIs in the management of squamous cell carcinoma of head and neck.对血管内皮生长因子酪氨酸激酶抑制剂（VEGF-TKIs）在头颈部鳞状细胞癌治疗中的现状及未来前景的批判性综述。
Front Oncol. 2023 Dec 13;13:1310106. doi: 10.3389/fonc.2023.1310106. eCollection 2023.
本文引用的文献
1
Successful treatment with docetaxel plus nintedanib in a patient with lung adenocarcinoma and pulmonary fibrosis: A case report and literature review.多西他赛联合尼达尼布成功治疗1例肺腺癌合并肺纤维化患者：病例报告及文献复习
Front Oncol. 2022 Aug 9;12:907321. doi: 10.3389/fonc.2022.907321. eCollection 2022.
2
The Effectiveness of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis, Familial Pulmonary Fibrosis and Progressive Fibrosing Interstitial Lung Diseases: A Real-World Study.尼达尼布在特发性肺纤维化、家族性肺纤维化和进行性纤维化间质性肺疾病患者中的有效性：一项真实世界研究。
Biomedicines. 2022 Aug 15;10(8):1973. doi: 10.3390/biomedicines10081973.
3
Effects of nintedanib on disease progression and safety in Japanese patients with progressive fibrosing interstitial lung diseases: Further subset analysis from the whole INBUILD trial.尼达尼布对进行性纤维化间质性肺疾病日本患者疾病进展和安全性的影响：来自整个 INBUILD 试验的进一步亚组分析。
Respir Investig. 2022 Nov;60(6):787-797. doi: 10.1016/j.resinv.2022.06.009. Epub 2022 Aug 1.
4
Safety, recommended dose, efficacy and immune correlates for nintedanib in combination with pembrolizumab in patients with advanced cancers.尼达尼布联合帕博利珠单抗治疗晚期癌症患者的安全性、推荐剂量、疗效和免疫相关性。
J Exp Clin Cancer Res. 2022 Jul 7;41(1):217. doi: 10.1186/s13046-022-02423-0.
5
Non-Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology.非小细胞肺癌，2022年第3版，美国国立综合癌症网络（NCCN）肿瘤学临床实践指南
J Natl Compr Canc Netw. 2022 May;20(5):497-530. doi: 10.6004/jnccn.2022.0025.
6
Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults: An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline.特发性肺纤维化（更新版）和成人进展性肺纤维化：美国胸科学会/欧洲呼吸学会/日本呼吸学会/拉丁美洲胸科学会临床实践指南。
Am J Respir Crit Care Med. 2022 May 1;205(9):e18-e47. doi: 10.1164/rccm.202202-0399ST.
7
Safety and tolerability of nintedanib in patients with progressive fibrosing interstitial lung diseases: data from the randomized controlled INBUILD trial.尼达尼布治疗进展性肺纤维化间质性肺病患者的安全性和耐受性：来自随机对照 INBUILD 试验的数据。
Respir Res. 2022 Apr 7;23(1):85. doi: 10.1186/s12931-022-01974-2.
8
Nintedanib plus Docetaxel after Immune Checkpoint Inhibitor Failure in Patients with Advanced Non-Small-Cell Lung Cancer: A Case Series.晚期非小细胞肺癌患者免疫检查点抑制剂治疗失败后使用尼达尼布联合多西他赛：病例系列
Case Rep Oncol. 2022 Feb 14;15(1):138-148. doi: 10.1159/000520939. eCollection 2022 Jan-Apr.
9
Impact of timing of nintedanib initiation among patients newly diagnosed with idiopathic pulmonary fibrosis.尼达尼布起始时间对新诊断的特发性肺纤维化患者的影响。
J Med Econ. 2022 Jan-Dec;25(1):532-540. doi: 10.1080/13696998.2022.2054203.
10
Exploration of radiation-induced lung injury, from mechanism to treatment: a narrative review.辐射诱导的肺损伤：从机制到治疗的探索：一篇叙述性综述
Transl Lung Cancer Res. 2022 Feb;11(2):307-322. doi: 10.21037/tlcr-22-108.
Zotero 插件